Starting with a best-in-class canine DNA test, Embark is building a powerful platform for scientific discovery that will accelerate advancements in personalized dog care. Embark’s dog DNA test— the most accurate and highest-rated on the market — helps educate pet owners about their dog’s breed, health, and ancestry. By using Embark’s products, customers can fuel new research and help all dogs (and, ultimately, humans) lead longer, healthier lives. Beyond its most recent genetic discoveries, Embark raised $75 million in Series B funding in 2021. Its continued growth will accelerate its ability to offer insights into certain conditions and make new discoveries about health risks, traits, and breeds. Embark is confident it can extend the lives of dogs by three years within the next decade by empowering dog owners with personalized, preventative care for their pets; giving breeders the tools they need to breed healthier dogs; and expanding the company’s research and partnerships to identify the genetic and other causes of healthy aging in dogs. As Embark’s database expands, it will be able to exponentially increase the number of novel discoveries it makes to help dogs live healthier, longer lives.